Pharmacology, Pharmacokinetics, Paclitaxel, Pharmacogenetics and Chemotherapy are his primary areas of study. His Pharmacology study combines topics from a wide range of disciplines, such as CYP3A4, Organic cation transport proteins, Toxicity and Docetaxel. His Docetaxel study deals with Taxane intersecting with Biological activity and Adverse effect.
His work deals with themes such as Oral administration, Irinotecan, Bioavailability and Drug, which intersect with Pharmacokinetics. His Paclitaxel research integrates issues from Dosage form, Neurotoxicity, Distribution and Pharmaceutical formulation. The various areas that Alex Sparreboom examines in his Pharmacogenetics study include Pharmacogenomics, Multidrug resistance-associated protein 2 and Allele frequency.
His main research concerns Pharmacology, Pharmacokinetics, Paclitaxel, Internal medicine and Chemotherapy. His Pharmacology research incorporates themes from Irinotecan, Toxicity and Docetaxel. His study looks at the relationship between Pharmacokinetics and fields such as Cancer, as well as how they intersect with chemical problems.
His studies deal with areas such as Taxane, Chromatography and Distribution as well as Paclitaxel. His study in Internal medicine is interdisciplinary in nature, drawing from both Gastroenterology, Endocrinology and Oncology. Alex Sparreboom works on Chemotherapy which deals in particular with Cisplatin.
Alex Sparreboom mostly deals with Pharmacology, Transporter, Cancer research, Pharmacokinetics and Drug. His Pharmacology research is multidisciplinary, relying on both Neurotoxicity, Tyrosine kinase, Nilotinib, Organic anion transporter 1 and Efflux. His study on Transporter also encompasses disciplines like
His Cancer research research incorporates elements of Leukemia, Paclitaxel and In vivo. His Pharmacokinetics study incorporates themes from Cancer, Area under the curve, Chromatography, Toxicity and Organic anion-transporting polypeptide. His Drug research is multidisciplinary, incorporating elements of Drug transporter and Distribution.
Alex Sparreboom mainly investigates Pharmacology, Transporter, Cancer research, Efflux and Sorafenib. His Pharmacology study incorporates themes from Tyrosine kinase, Nilotinib, Organic anion transporter 1, Tyrosine-kinase inhibitor and Drug resistance. His Organic anion transporter 1 research focuses on subjects like Taxane, which are linked to Docetaxel.
His Cancer research research is multidisciplinary, incorporating perspectives in RNA, Immune system, Prodrug, Toxicity and Breast cancer. His biological study spans a wide range of topics, including Endocrinology, Glucuronide, Xenobiotic and Hepatocyte. Alex Sparreboom interconnects Cancer and Pharmacokinetics in the investigation of issues within Genetic model.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation.
Hans Gelderblom;Jaap Verweij;Kees Nooter;Alex Sparreboom.
European Journal of Cancer (2001)
Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine
A. Sparreboom;J. van Asperen;U. Mayer;A.H. Schinkel.
Proceedings of the National Academy of Sciences of the United States of America (1997)
Clinical pharmacokinetics and metabolism of irinotecan (CPT-11)
Ron H. J. Mathijssen;Robbert J. van Alphen;Jaap Verweij;Walter J. Loos.
Clinical Cancer Research (2001)
Pharmacological effects of formulation vehicles : implications for cancer chemotherapy.
Albert J ten Tije;Jaap Verweij;Walter J Loos;Alex Sparreboom;Alex Sparreboom.
Clinical Pharmacokinectics (2003)
Herbal Remedies in the United States: Potential Adverse Interactions With Anticancer Agents
Alex Sparreboom;Michael C. Cox;Milin R. Acharya;William D. Figg.
Journal of Clinical Oncology (2004)
Appropriate Chemotherapy Dosing for Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline
Jennifer J. Griggs;Pamela B. Mangu;Holly Anderson;Edward P. Balaban.
Journal of Clinical Oncology (2012)
Effects of St. John's Wort on Irinotecan Metabolism
Ron H. J. Mathijssen;Jaap Verweij;Peter de Bruijn;Walter J. Loos.
Journal of the National Cancer Institute (2002)
Comparative Preclinical and Clinical Pharmacokinetics of a Cremophor-Free, Nanoparticle Albumin-Bound Paclitaxel (ABI-007) and Paclitaxel Formulated in Cremophor (Taxol)
Alex Sparreboom;Charity D. Scripture;Vuong Trieu;Paul J. Williams.
Clinical Cancer Research (2005)
Phase I and Pharmacokinetic Study of MS-275, a Histone Deacetylase Inhibitor, in Patients With Advanced and Refractory Solid Tumors or Lymphoma
Qin C. Ryan;Donna Headlee;Milin Acharya;Alex Sparreboom.
Journal of Clinical Oncology (2005)
Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications.
Alex Sparreboom;Lia van Zuylen;Eric Brouwer;Walter J. Loos.
Cancer Research (1999)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: